[Soluble tumor-necrosis-factor-alpha receptor type-1 as a marker of activity of psoriasis vulgaris and effects of its treatment].
The aim of the study was to examine the concentration of soluble tumor necrosis factor alpha type I (sTNF-R1) in patients with psoriasis vulgaris in relation to the severity of skin lesions and the effects of treatment.


METHODS
the study was conducted among 34 patients. The assessment of the severity of skin lesions (Psoriasis Area and Severity Index -PASI), and the serum concentration of sTNF-R1 (ELISA) were performed at baseline and after 2 weeks of treatment. Control sera were obtained from 30 healthy volunteers.


RESULTS
pretreatment PASI was 12.98 +/- 5.77 and after two-week treatment 6.17 +/- 2.12 (p < 0.05), sTNF-R1 concentration 1.88 +/- 0.41 ng/mL and 1.65 +/- 0.46 ng/mL, respectively (p < 0.05). Serum concentration of sTNF-R1 was significantly lower in controls (1.48 +/- 0.30 ng/mL) as compared with its pre-treatment level in psoriasis patients. A significant correlation between pre-treatment PASI and concentration of sTNF-R1 was found (r = 0.40, p < 0.05).


CONCLUSIONS
serum concentration of sTNF-R1 can be a sensitive marker of activity of psoriasis vulgaris and decreases following the effective treatment.
Serwin
Agnieszka Beata
AB
Klinika Dermatologii i Wenerologii, Akademii Medycznej w Bialymstoku. agabster@amb.edu.pl
Sokołowska
Marianna
M
Chodynicka
Bozena
B
D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000097:blood* / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood* / Q000187:drug effects*; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D013997:Time Factors
D015415:Biomarkers; D018124:Receptors, Tumor Necrosis Factor